The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors with genetic mutations that make them resistant to these anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, or the cancers develop resistance during treatment.
News: Home Page Research
A recent study by Dai Chung, M.D., and colleagues suggests new therapeutic options for Ewing sarcoma, a type of rare, aggressive childhood cancer.
Three breast cancer investigators from Vanderbilt-Ingram Cancer Center (VICC) have been awarded research grants from Susan G. Komen, a nonprofit foundation devoted to supporting cancer research, community health outreach, advocacy and public policy initiatives.
In a study published in the journal Scientific Reports, Alexander Zaika, Ph.D. and coworkers show that DNA damage in the esophageal cells caused by acidic bile reflux (BA/A) activates enzymes called NADPH oxidases in the mitochondria, the cell’s power house, to release highly reactive-oxygen species (ROS).
Pancreatic ductal carcinoma (PDAC) is one of the most lethal types of cancer, with new therapeutic options needed. Sergey Novitskiy, M.D., Ph.D., and colleagues investigated the immune response during the development of aggressive PDAC in an animal model of the disease.
Dietary intake of polyunsaturated fatty acids (PUFAs) has been associated with risk of colorectal cancer, with omega-6 PUFAs increasing and omega-3 PUFAs decreasing risk. Most studies, however, have relied on questionnaires to assess consumption of fatty acids, and results have been inconsistent. Harvey Murff, M.D., and colleagues have studied a blood-based biomarker of PUFA intake. […]
A group of nationally recognized medical information and data management experts has recommended the development of new knowledge software applications that work alongside electronic health record systems (EHRs) to help practicing oncologists access and use the latest genomic information to assist in the treatment of cancer patients. The recommendations were unveiled in a new report […]
Thanks to advances in treatment, the relative five-year survival rate from all combined subtypes of breast cancer now exceeds 90 percent and yet the disease remains the third leading cause of cancer deaths in the United States after lung and colorectal cancers. Carlos L. Arteaga, M.D. More than 40,000 American women will die from breast […]
Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients. They identified a novel gene mutation that develops in the tumors, and then found a different cancer drug that appears to treat the newly identified mutation. The […]
Overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 25 percent of breast cancers and is associated with poor outcomes. HER2-amplified breast cancers use signaling through a complex of proteins called mTORC2 to drive tumor formation, tumor cell survival and resistance to HER2-targeted therapies. Rebecca Cook, Ph.D., and colleagues have now […]